Biologic therapy for inflammatory bowel disease comes of age

  • Stephen B. Hanauer
Clinical Trials Report


  1. 1.
    Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003, 348:601–608.PubMedCrossRefGoogle Scholar
  2. 2.
    Hanauer SB, Wagner CL, Bala M, et al.: Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2004, 2:542–553.PubMedCrossRefGoogle Scholar
  3. 3.
    Wong M, Ziring D, Korin Y, et al.: TNFα blockade in human diseases: mechanisms and future directions. Clin Immunol 2008, 126:121–136.PubMedCrossRefGoogle Scholar
  4. 4.
    Vermeire S, Noman M, Van Assche G, et al.: Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut 2007, 56:1226–1231.PubMedCrossRefGoogle Scholar
  5. 5.
    Colombel JF, Sandborn WJ, Rutgeerts P, et al.: Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007, 132:52–65.PubMedCrossRefGoogle Scholar
  6. 6.
    Sandborn WJ, Feagan BG, Stoinov S, et al.: Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007, 357:228–238.PubMedCrossRefGoogle Scholar
  7. 7.
    Toruner M, Loftus EV Jr, Harmsen WS, et al.: Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929–936.PubMedCrossRefGoogle Scholar
  8. 8.
    Hanauer SB: Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: Is the synergy worth the risk? Gut 2007, 56:1181–1183.PubMedCrossRefGoogle Scholar
  9. 9.
    Rutgeerts P, Feagan BG, Lichtenstein GR, et al.: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004, 126:402–413.PubMedCrossRefGoogle Scholar
  10. 10.
    Kandiel A, Fraser AG, Korelitz BI, et al.: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54:1121–1125.PubMedCrossRefGoogle Scholar
  11. 11.
    Markowitz J, Grancher K, Kohn N, et al.: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 2000, 119:895–902.PubMedCrossRefGoogle Scholar
  12. 12.
    van der Kooij SM, Allaart CF, Dijkmans BA, Breedveld FC: Innovative treatment strategies for patients with rheumatoid arthritis. Curr Opin Rheumatol 2008, 20:287–294.PubMedCrossRefGoogle Scholar
  13. 13.
    Lemann M, Mary JY, Duclos B, et al.: Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology 2006, 130:1054–1061.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Stephen B. Hanauer

There are no affiliations available

Personalised recommendations